Bihari C. Hepatic sarcoidosis: clinico-pathological characterization of symptomatic cases. Acta Gastroenterol Belg. Rheum Dis Clin North Am. Characteristics and long-term outcome of neurosarcoidosis: a population-based study from Allen R. A prospective study of 32 patients with neurosarcoidosis. Ferriby D. Long-term follow-up of neurosarcoidosis.
Joseph F. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry. Nozaki K. Neurosarcoidosis: clinical manifestations, diagnosis and treatment.
Presse Med. Carlson M. Cranial base manifestations of neurosarcoidosis: a review of patients. Otol Neurotol. Pawate S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. Zajicek J. Central nervous system sarcoidosis—diagnosis and management. Krumholz A. Clinical implications of seizures in neurosarcoidosis.
Arch Neurol. Stern B. Neurosarcoidosis Study Group. Neurologic presentations of sarcoidosis. Neurol Clin. Tavee J. Berliner A. Sarcoidosis: the nephrologist's perspective. Am J Kidney Dis. Longcope W. A study of sarcoidosis; based on a combined investigation of cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital.
Medicine Baltimore ; 31 1 :1— Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine Baltimore ; 88 2 — Kamata Y. Clinical characteristics of biopsy-proven renal sarcoidosis in Japan. Kandolin R. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.
Chapelon-Abric C. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine Baltimore ; 83 6 — Hamzeh N. Pathophysiology and clinical management of cardiac sarcoidosis. Nat Rev Cardiol. Causes of death in patients with chronic sarcoidosis.
Hunninghake G. Birnie D. HRS expert consensus statement on the diagnosis and management of arrythmias associated with cardiac sarcoidosis.
Heart Rhythm. Ebert E. Gastrointestinal and hepatic manifestations of sarcoidosis. Afshar K. Gastric sarcoidosis and review of the literature. J Natl Med Assoc. A rare case of symptomatic gastric sarcoidosis. The diagnosis of sarcoidosis. Govender P. Does CT scanning predict the likelihood of a positive transbronchial biopsy in sarcoidosis?
Shorr A. Endobronchial biopsy for sarcoidosis: a prospective study. Polychronopoulos V. Airway involvement in sarcoidosis. Bradley B. Uemura A. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J.
Cardiac sarcoidosis. J Am Coll Cardiol. Chareonthaitawee P. J Nucl Cardiol. Herbort C. Lieberman J. Elevation of serum angiotensin-converting-enzyme ACE level in sarcoidosis. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Bunting P. Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis.
Clin Biochem. Spagnolo P. Pulmonary sarcoidosis. Lancet Respir Med. Migita K. Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease.
Medicine Baltimore ; 92 5 — Maradit Kremers H. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum. The treatment of pulmonary sarcoidosis. West S. Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations. Curr Opin Rheumatol. Carmona E. Pulmonary sarcoidosis: diagnosis and treatment. Treatment of sarcoidosis. Clin Rev Allergy Immunol. Schutt A.
Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Paramothayan S. Treatment for pulmonary sarcoidosis. Methotrexate is steroid sparing in acute sarcoidosis: results of double blind, randomized trial. Lower E. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci. Vucinic V. What is the future of methotrexate in sarcoidosis? Vorselaars A. Crommelin H. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Kamphuis L.
Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Sweiss N. Efficacy results of a week trial of adalimumab in the treatment of refractory sarcoidosis. Utz J. Rituximab in the treatment of refractory pulmonary sarcoidosis. Cinetto F. Rituximab in refractory sarcoidosis: a single centre experience.
Clin Mol Allergy. Ann Intern Med 12 —23, W TPMT testing in rheumatology: any better than routine monitoring? Rheumatol Oxford 46 5 —9. Eur Respir J 14 5 — Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis.
Sarcoidosis Vasc Diffuse Lung Dis 16 1 — Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med 2 Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med 11 —9. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 76 13 — Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration 86 5 — The treatment of sarcoidosis with chloroquine. Am J Med 30 — Schrezenmeier E, Dorner T.
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16 3 — Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement.
Arch Neurol 55 9 — Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 30 2 — Evidence-based therapy for cutaneous sarcoidosis.
Clin Dermatol 25 3 — Lung 2 — No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 3 — Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis.
Sarcoidosis 11 2 — Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19 3 — Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol 18 6 —9.
Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 1 —6. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis 32 4 — Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.
Eur Respir J 31 6 — Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.
Semin Arthritis Rheumatol 43 1 — BioDrugs 31 4 — Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68 11 — N Engl J Med 7 —8. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 31 1 — A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis.
J Am Acad Dermatol 68 5 — Clin Respir J 6 4 — Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.
Graefes Arch Clin Exp Ophthalmol 5 — Anti-TNF-alpha therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum 45 3 —8. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med —7. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2 — Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 44 5 — A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
Ann Rheum Dis 72 10 — Efficacy and safety of infliximab biosimilar Inflectra R in severe sarcoidosis. Respir Med S :S7—S Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.
J Neurol 5 —8. Infliximab or biosimilars in sarcoidosis; to switch or not to switch? Sarcoidosis Vasc Diffuse Lung Dis 32 4 —3. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis.
Clin Vaccine Immunol 18 8 — Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity. Rheumatol Oxford 52 9 — Perigranuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis? Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine 75 4 —2. A case of neurosarcoidosis successfully treated with rituximab.
Neurology 75 6 — Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 43 5 —8. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 6 —8. N Engl J Med 18 — JAMA Neurol 74 11 — Demeter SL.
Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest 94 1 —3. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 16 —8. Repository corticotropin for Chronic Pulmonary Sarcoidosis. Lung 3 — Pentoxifylline in treatment of sarcoidosis. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.
Sarcoidosis Vasc Diffuse Lung Dis 26 2 — Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol 9 —9. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 30 3 — Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
Arch Dermatol 2 —4. Contemp Clin Trials Commun 19 A [ CrossRef ] [ Google Scholar ]. J Immunol 4 — Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression.
Nat Immunol 18 3 — J Immunol 9 — Blood 13 —8. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells.
Calcium and vitamin D in sarcoidosis: is supplementation safe? J Bone Miner Res 29 11 — Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. J Invest Med 64 5 — Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy.
Relapses of sarcoidosis: what are they and can we predict who will get them? Eur Respir J 43 2 —9. Sarcoidosis Vasc Diffuse Lung Dis 16 2 — British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 51 3 — Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 99 5 — Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis.
Eur Respir J 51 1. Hum Immunol 80 1 —9. Am J Pathol 2 — The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2 — Clin Vaccine Immunol 18 2 — Tarasidis A, Arce S. Immune response biomarkers as indicators of sarcoidosis presence, prognosis, and possible treatment: An Immunopathogenic perspective. Autoimmun Rev 19 3 Eur Respir J 43 6 —9. Clin Exp Immunol 2 — Chest 6 —5. Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns.
FRes 8 Bone health issues in sarcoidosis. Curr Rheumatol Rep 13 3 — Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med :9— Drug-Induced Sarcoidosis-Like Reactions. Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza Other Respir Viruses 6 2 — Pneumococcal vaccine and patients with pulmonary diseases.
Am J Med 9 e1—8. Arthritis Rheumatol 69 8 — Arthritis Care Res Hoboken 68 1 :1— From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis. The kinds of tests and experimental treatments involved. How the possible risks, side effects and benefits compare with your current treatment. Who will pay for the experimental treatment and other related expenses. What type of long-term follow up care is part of this study.
Understanding Clinical Trial Keywords placebo: an inactive pill, liquid or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the effectiveness.
In clinical trials, one group of participants is given an experimental drug, while another group the control group is given either a standard treatment or a placebo. Join the Sarcoidosis Patient Registry. Learn about FSR funding opportunities.
Take Action Learn how you can help. Find a doc For info and treatment.
0コメント